Clinical Trial Update: Erlotinib Versus Gemcitabine/Carboplatin in Chemo-naive Stage IIIB/IV Non-Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Exon 19 or 21 Mutation [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial comparing erlotinib to gemcitabine/carboplatin in chemo-naive stage IIIB/IV non-small cell lung cancer patients with EGFR exon 19 or 21…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• CARBOPLATIN (Carboplatin)
• ERLOTINIB (Erlotinib)
• Gemcitabine (Gemcitabine)

Snippet

Sponsor: Tongji University | Conditions: Non-small Cell Lung Cancer | Phase 3 | Status: COMPLETED